Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia.

In alternative embodiments, provided are compositions, e.g., pharmaceutical compositions, formulations, kits and other products of manufacture, comprising a hydrogel and active ingredients, including mixed thickness skin micrografts, or full or split-thickness skin grafts, contained or mixed in or within the hydrogel; and methods for making and using them. In alternative embodiments, compositions and methods as provided herein are used for the treatment or amelioration of wounds and surgical sites, and include compositions and methods for micrografting, or for micrografting a wound, or for micrografting a wound for rapid re-epithelialization, or for micrografting a wound for rapid re-epithelialization of large non-healing wounds.

In alternative embodiments, provided are compositions, e.g., pharmaceutical compositions, formulations, kits and other products of manufacture, comprising a hydrogel and active ingredients, including mixed thickness skin micrografts, or full or split-thickness skin grafts, contained or mixed in or within the hydrogel; and methods for making and using them. In alternative embodiments, compositions and methods as provided herein are used for the treatment or amelioration of wounds and surgical sites, and include compositions and methods for micrografting, or for micrografting a wound, or for micrografting a wound for rapid re-epithelialization, or for micrografting a wound for rapid re-epithelialization of large non-healing wounds.

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

A method for inhibiting renal hypofunction in a non-human animal includes administering cat-derived erythropoietin to the non-human animal. The non-human animal may have renal hypofunction. The non-human animal may have chronic kidney disease and the renal hypofunction may be caused by the chronic kidney disease. The cat-derived erythropoietin may be administered repeatedly at a time interval of 7 to 30 days.

This disclosure relates to nanoparticles, compositions, methods of making, and methods of use thereof.

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia® (denosumab), Xgeva® (denosumab), Aranesp® (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102).

The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.

This invention is directed to the use of a chorionic gonadotrophin carboxy terminal peptide (CTP) or fragments thereof for modifying a polypeptide or a fragment thereof in order to increase the hydrodynamic volume of the polypeptide or fragment thereof.

The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.